Compare WHWK & JFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHWK | JFIN |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | China |
| Employees | 23 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.4M | 201.5M |
| IPO Year | N/A | 2018 |
| Metric | WHWK | JFIN |
|---|---|---|
| Price | $4.04 | $4.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 442.8K | 86.2K |
| Earning Date | 05-06-2026 | 06-03-2026 |
| Dividend Yield | N/A | ★ 17.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $3.70 |
| 52 Week High | $5.50 | $18.70 |
| Indicator | WHWK | JFIN |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 39.31 |
| Support Level | $3.72 | $3.80 |
| Resistance Level | $4.38 | $4.54 |
| Average True Range (ATR) | 0.33 | 0.26 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 6.80 | 27.39 |
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.